-
Citi Discusses Covidien's Earnings (COV)
Thursday, April 21, 2011 - 11:24am | 126Citi Investment Research has a Buy rating and a $64 price target on shares of Covidien Ltd (NYSE: COV) following the company's earnings report. In a note to investors, Citi writes, "Management is raising F2011 guidance with sales now expected to increase +8-11%, up 200bps vs. prior range, which...
-
Puts Purchased on Covidien (COV)
Thursday, April 21, 2011 - 11:16am | 135Shares of Covidien Public Limited Company (NYSE: COV) are higher on the session by 1.89%, currently trading at $54.89. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the...
-
Puts Purchased on Covidien (COV)
Thursday, April 21, 2011 - 11:14am | 135Shares of Covidien Public Limited Company (NYSE: COV) are higher on the session by 1.89%, currently trading at $54.89. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the...
-
Wedbush Reports Solid Q1 Results For Edwards Lifesciences
Thursday, April 21, 2011 - 10:19am | 123According to Wedbush, Edwards Lifesciences (NYSE: EW) saw solid Q1 2011 results that beat expectations. Wedbush said that EW reports Q1:2011 revenues of $404.5MM and EPS of $0.53, compared to estimates of $392.0MM and $0.42 and consensus of $384.1 million and $0.42. “EW reported very strong Q1:11...
-
Piper Jaffray Comments On Baxter Q1 Results
Thursday, April 21, 2011 - 9:39am | 171According to Piper Jaffray, Baxter International (NYSE: BAX) Q1 results were strong across the board with a solid beat in the company's Bioscience (+$68MM) and Medication Delivery (+$73MM). Piper Jaffray said that within the segments, the Bioscience beat was driven by the key franchises of...
-
Gabelli Raising Estimates On Edwards Lifesciences Corp (EW)
Thursday, April 21, 2011 - 9:26am | 130Gabelli & Co. is raising its estimates on Edwards Lifesciences Corp (NYSE: EW) following earnings. In a note to clients, Gabelli writes, "We are raising our 2011 EPS estimate to $2.05 from $1.95, as gross margins will be at the low end of guidance due to FX, but higher revenue and operating...
-
Wedbush Upgrades Edwards Lifesciences To Neutral, PT To $78
Thursday, April 21, 2011 - 9:01am | 28Wedbush Securities has upgraded Edwards Lifesciences (NYSE: EW) from Underperform to Neutral and has raised the price target from $75 to $78.
-
Deutsche Bank Rates Edwards At Hold
Thursday, April 21, 2011 - 8:31am | 123According to Deutsche Bank, Edwards Lifesciences (NYSE: EW) transcatheter heart valve (THV) sales were $72.7M (inclusive of $2-$3M in stocking) and were ahead of DB est of $68M. Deutsche Bank said that sales were also higher than 4Q10's $65.3M (which included $3-4M in stocking) and well ahead of...
-
Boston Scientific Rises After Reporting Q1 Profit
Thursday, April 21, 2011 - 8:31am | 141Shares of Boston Scientific Corp (NYSE: BSX) gained about 2% in pre-market trading after the company reported a Q1 profit and raised its earnings per share guidance for the full year. The company's Q1 net earnings came in at $20 million, or $0.01 per share, versus a loss of $1.59 million, or a...
-
Wedbush Raises PT On STJ To $46
Thursday, April 21, 2011 - 8:26am | 124Wedbush, citing a solid quarter on track with expectations, has raised its price target on St. Jude Medical (NYSE: STJ) from $38 to $46. According to Wedbush, “St. Jude Medical reported first quarter results that reflected strong product sales, improving gross margins, and solid execution across...
-
J.P. Morgan Raises PT On EW To $78
Thursday, April 21, 2011 - 7:51am | 148J.P. Morgan is raising its price target on Edwards Lifesciences (NYSE: EW) from $76 to $78 based upon an impressive 1Q. In the report, J.P. Morgan writes, “Edwards reported strong 1Q results Wednesday night, with sales of $404.5M (+18.8% reported, +17.1% underlying) coming in $20M above Street...
-
J.P. Morgan Comments On BSX 1Q, Anticipates 8AM Call
Thursday, April 21, 2011 - 7:49am | 125J.P. Morgan reports that Boston Scientific (NYSE: BSX) reported 1Q results Wednesday night, with sales of $1.925B (-1.8% reported, -0.7% organic) coming in $30M ahead of the Street “and $18M above our own forecast, due in large part to currency.” “The big story in the quarter, though, is down the...
-
Deutsche Bank Raises PT On St. Jude Medical To $60
Thursday, April 21, 2011 - 7:30am | 28Deutsche Bank has raised the price target on St. Jude Medical (NYSE: STJ) from $57 to $60 and maintains its Buy rating.
-
J.P. Morgan Reiterates OW Rating On STJ
Thursday, April 21, 2011 - 7:26am | 103J.P. Morgan is reiterating its Overweight rating on shares of St. Jude Medical Inc. (NYSE: STJ). “St. Jude reported strong 1Q results Wednesday morning,” J.P. Morgan writes. “Revenues of $1.376B increased 9.0% reported and 4.6% organic, in-line with consensus. Sales were driven by a solid...
-
Deutsche Bank Reports Reovery A Ways Off For Boston Scientific
Thursday, April 21, 2011 - 7:25am | 122According to Deutsche Bank, Boston Scientific (NYSE: BSX) is facing another Guidant CRM impairment charge. Deutsche Bank said that recovery is still some way off. “Boston Scientific closed the Guidant acquisition exactly 5 years ago today for an aggregate purchase price of $28.4B, selling the...